The role of somatostatin receptors in the medical treatment of acromegaly

Digestive and Liver Disease

Volumn 36, Issue SUPPL. 1, 2004, Pages

  Vitale, G ^a   Pivonello, R ^a   Ferone, D ^b   De Martino, M C ^a   Auriemma, R S ^a   Caraglia, M ^c   Abbruzzese, A ^c   Lombardi, G ^a   Colao, A ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Acromegaly; Lanreotide; Octreotide; Somatostatin receptors

Indexed keywords

ANGIOPEPTIN; GROWTH HORMONE; OCTREOTIDE; PENTETATE INDIUM IN 111; SOMATOMEDIN C; SOMATOSTATIN; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; SOMATOSTATIN RECEPTOR 1; SOMATOSTATIN RECEPTOR 2; SOMATOSTATIN RECEPTOR 3; SOMATOSTATIN RECEPTOR 4; SOMATOSTATIN RECEPTOR 5; CYCLOPEPTIDE; DRUG DERIVATIVE;

ACROMEGALY; AUTORADIOGRAPHY; BIOCHEMISTRY; CARDIOVASCULAR DISEASE; CELL PROLIFERATION; DOSE RESPONSE; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; GROWTH INHIBITION; HISTOPATHOLOGY; HORMONE RELEASE; HUMAN; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; INDIVIDUALIZATION; INHIBITION KINETICS; MOLECULAR BIOLOGY; PATIENT CARE; PATIENT COMPLIANCE; PREDICTION; PROTEIN EXPRESSION; RECEPTOR BINDING; REVIEW; SCINTISCANNING; SLOW RELEASE FORMULATION; TREATMENT OUTCOME; TUMOR CELL; TUMOR GROWTH; UNNECESSARY PROCEDURE;

ACROMEGALY; HUMANS; OCTREOTIDE; PEPTIDES, CYCLIC; SOMATOSTATIN;

EID: 2442654223     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dld.2003.11.022     Document Type: Article

References (48)

1. Patel YC. Somatostatin and its receptors. Front Neuroendocrinol 1999;20:157-98.
2. Epelbaum J, Dournaud P, Fodor M, Viollet C. The neurobiology of somatostatin. Crit Rev Neurobiol 1994;8:25-44.
3. Benali N, Ferjoux G, Puente E, Buscail L, Susini C. Somatostatin receptors. Digestion 2000;62:27-32.
4. Shimon I, Taylor JE, Dong JZ, Bitonte RA, Kim S, Morgan B, et al. Somatostatin receptor subtype specificity in human fetal pituitary cultures. J Clin Invest 1997;99:789-98.
5. Shimon I, Yan X, Taylor JE, Weiss MH, Culler MD, Helmed S. Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. J Clin Invest 1997;100:2386-92.
6. Shimon I, Helmed S. Management of pituitary tumors. Ann Intern Med 1998;129:472-83.
7. Colao A, Lombardi G. Growth hormone and prolactin excess. Lancet 1998;352:1455-61.
8. Arosio H, Hacchelli S, Rossi CH, Casati G, Biella O, Faglia G. Effects of treatment with octreotide in acromegalic patients - a multicenter Italian study. Italian Multicenter Octreotide. Eur J Endocrinol 1995;133:430-9.
9. Colao A, Ferone D, Marzullo P, Cappabianca P, Cirillo S, Boerlin V, et al. Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. J Clin Endocrinol Hetab 2001;86:2779-86.
10. Sevan JS, Atkins SL, Bouloux PM, Hanna F, Harris PE, James RA, et al. Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size. J Clin Endocrinol Metab 2002;87:4554-63.
11. Verhelst JA, Pedroncelli AM, Abs R, Montini M, Vandeweghe MV, Albani G, et al. Slow-release lanreotide in the treatment of acromegaly: a study in 66 patients. Eur J Endocrinol 2000;143:577-84.
12. Attanasio R, Barausse M, Cozzi R. GH/IGF-1 normalization and tumor shrinkage during long-term treatment of acromegaly by lanreotide. J Endocrinol Invest 2001;24:209-16.
13. Ezzat S, Snyder PJ, Young WF, Boyajy LD, Newman C, Klibanski A, et al. Octreotide treatment of acromegaly. A randomized, multicenter study. Ann Intern Med 1992;117:711-8.
14. Lancranjani I, Bruns C, Grass P, Jaquet P, Jervell J, Kendall-Taylor P, et al. Sandostatin LAR a promising therapeutic tool in the management of acromegalic patients. Metabolism 1996;45:67-71.
15. Gillis JC, Noble S, Goa KL. Octreotide long-acting release (LAR). A review of its pharmacological properties and therapeutic use in the management of acromegaly. Drugs 1997;53:681-99.
16. Caron P, Morange-Ramos I, Conge M, Jaquet P. Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide. J Clin Endocrinol Metab 1997;82:18-22.
17. Colao A, Marzullo P, Lombardi G, Italian Multicenter Study Group on Lanreotide. Effect of a six-month treatment with lanreotide on cardiovascular risk factors and arterial intima-media thickness in patients with acromegaly. Eur J Endocrinol 2002;146:303-9.
18. Giusti M, Gussoni G, Cuttica CM, Giordano G. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: six month report on an Italian multicenter study. Italian Multicenter Slow Release Lanreotide Study Group. J Clin Endocrinol Metab 1996;81:2089-97.
19. Baldelli R, Colao A, Razzore P, Jaffrain-Rea ML, Marzullo P, Ciccarelli E, et al. Two-year follow-up of acromegalic patients treated with slow release lanreotide (30 mg). J Clin Endocrinol Metab 2000;85:4099-103.
20. Caron P, Beckers A, Cullen DR, Goth MI, Gutt B, Laurberg P, et al. Efficacy of the new long-acting formulation of lanreotide (lanreotide autogel) in the management of acromegaly. J Clin Endocrinol Metab 2002;87:99-104.
21. Newman CB. Medical therapy for acromegaly. Endocrinol Metab Clin North Am 1999;28:171-90.
22. Detenbeck L, Tressler H, O'Duffy J, Randall RV. Peripheral joint manifestations of acromegaly. Clin Orthop 1973;91:119-27.
23. Colao A, Marzullo P, Vallone G, Giaccio A, Ferone D, Rossi E, et al. Ultrasonographic evidence of joint thickening reversibility in acromegalic patients treated with lanreotide for 12 months. Clin Endocrinol 1999;51:611-8.
24. Colao A, Cuocolo A, Marzullo P, Nicolai E, Ferone D, Della Morte AM, et al. Is the acromegalic cardiomyopathy reversible? Effect of 5-year normalization of growth hormone and insulin-like growth factor I levels on cardiac performance. J Clin Endocrinol Metab 2001;86:1551-7.
25. Tokgözoglu SL, Erbas T, Aytemir K, Akalin S, Kes S, Oram E. Effects of octreotide on left ventricular mass in acromegaly. Am J Cardiol 1994;74:1072-4.
26. Merola B, Cittadini A, Colao A, Ferone D, Fazio S, Sabatini D, et al. Chronic treatment with the somatostatin analog octreotide improves cardiac abnormalities in acromegaly. J Clin Endocrinol Metab 1993;77:790-3.
27. Pereira J, Rodriguez-Puras MJ, Leal-Cerro A, Martinez A, Garcial-Luna PP, Gavilan I, et al. Acromegalic cardiopathy improves after treatment with increasing doses of octreotide. J Endocrinol Invest 1991;14:17-23.
28. Colao A, Cuocolo A, Marzullo P, Nicolai E, Ferone D, Florimonte L, et al. Effects of one-year treatment with octreotide on cardiac performance in patients with acromegaly. J Clin Endocrinol Metab 1999;84:17-23.
29. Chanson P, Timsit J, Masquet C, Guillausseau PJ, Warnet A, Lubetzi J. Heart failure responsive to octreotide in patient with acromegaly. Lancet 1989;1:1263-4.
30. Chanson P, Timsit J, Masquet C, Warnet A, Guillausseau PJ, Birman P, et al. Cardiovascular effects of the somatostatin analog octreotide in acromegaly. Ann Intern Med 1990;113:921-5.
31. Giustina A, Boni E, Romanelli G, Grassi V, Giustina G. Cardiopulmonary performance during exercise in acromegaly, and the effects of acute suppression of growth hormone hypersecretion with octreotide. Am J Cardiol 1995;75:1042-7.
32. Baldelli R, Ferretti E, Jaffrain-Rea ML, Iacobellis G, Minniti G, Caracciolo B, et al. Cardiac effects of lanreotide, a slow release somatostatin analog, in acromegalic patients. J Clin Endocrinol Metab 1999;84:527-32.
33. Colao A, Marzullo P, Ferone D, Spinelli L, Cuocolo A, Bonaduce D, et al. Cardiovascular effects of depot long-acting somatostatin analog Sandostatin LAR® in acromegaly. J Clin Endocrinol Metab 2000;86:3132-40.
34. Ur E, Mather SJ, Bomanji J, Ellison D, Britton KE, Grossman AB, et al. Pituitary imaging using a labelled somatostatin analogue in acromegaly. Clin Endocrinol 1992;36:147-50.
35. Reubi JC, Landolt AM. The growth hormone responses to octreotide in acromegaly correlates with adenoma somatostatin receptor status. J Clin Endocrinol Metab 1989;68:844-50.
36. Greenman Y, Melmed S. Heterogeneous expression of two somatostatin receptor subtypes in pituitary tumours. J Clin Endocrinol Metab 1994;78:398-403.
37. Lamberts SNJ, Uitterlinden P, Schuijff PC, Klijn P. Therapy of acromegaly with sandostatin: the predictive value of an acute test, the value of serum somatomedin-C measurements in dose adjustment and the definition of a biochemical cure. Clin Endocrinol 1988;29:411-20.
38. Pieters GFFM, Smals AGH, Kloppenborg PWC. Long-term treatment of acromegaly with the somatostatin analogue SMS 201-995. N Engl J Med 1986;314:1391.
39. Lamberts SNJ, Uitterlinden P, Del Pozo E. SMS 201-995 induces a continuous decline in circulating growth hormone and somatomedin-C levels during therapy of acromegalic patients for over 2 years. J Clin Endocrinol Metab 1987;65:703-10.
40. Plockinger U, Bader M, Hopfenmuller W, Saeger W, Quabbe HJ. Results of somatostatin receptor scintigraphy do not predict pituitary tumor volume and hormone-response to octeotide therapy and not correlate with tumor histology. Eur J Endocrinol 1997;136:369-76.
41. Colao A, Ferone D, Lastoria S, Marzullo P, Cerbone G, Di Sarno A, et al. Prediction of efficacy of octeotide therapy in patients with acromegaly. J Clin Endocrinol Metab 1996;81:2356-62.
42. 2 receptor scintigraphy. Clin Endocrinol 2001;54:469-77.
43. Colao A, Ferone D, Lastoria S, Marzullo P, Cerbone G, Di Sarno A, et al. Prediction of efficacy of octreotide therapy in patients with acromegaly. J Clin Endocrinol Metab 1996;81:2356-62.
44. 111In-DTPA-D-Phe-octreotide in the normal pituitary and in pituitary adenomas. J Endocrinol Invest 1999;22:176-83.
45. Savenau A, Gunz G, Dufour H, Caron P, Fina F, Ouafik L, et al. BIM-23244, a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas. J Clin Endocrinol Metab 2001;86:140-5.
46. Jaquet P, Saveanu A, Gunz G, Fina F, Zamora AJ, Grino M, et al. Human somatostatin receptor subtypes in acromegaly: distinct patterns of messenger ribonucleic acid expression and hormone suppression identify different tumoral phenotypes. J Clin Endocrinol Metab 2000;85:781-92.
47. Lombardi G, Colao A, Ferone D, Sarnacchiaro F, Marzullo P, Di Sarno A, et al. CV 205-502 treatment in therapy-resistant acromegalic patients. Eur J Endocrinol 1995;132:559-64.
48. Rocheville M, Lange DC, Kumar U, Patel SC, Patel RC. Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. Science 2000;288:154-7.